title: Safety profile of meropenem: an updated review of over 6,000 patients treated with meropenem.
abstract: Meropenem is a broad-spectrum carbapenem antibacterial with potent antimicrobial activity against a broad range of Gram-negative, Gram-positive and anaerobic bacteria. The second parenteral carbapenem to be introduced worldwide, meropenem has been in clinical use since 1994. Two previous safety reviews have established that meropenem has a favourable and acceptable safety profile. This new review was conducted after the approval of meropenem in the US in 2005 for the treatment of patients with complicated skin and skin-structure infections, in addition to the previously approved indications of intra-abdominal infections and paediatric bacterial meningitis. The analysis includes the clinical trial data from the previous safety reviews, updated with expanded experience across a number of serious bacterial infections, including a large international study in patients with skin or skin-structure infections and further experience in patients with intra-abdominal infections and bacterial meningitis. A total of 6154 patients with 6308 meropenem exposures were compared with 4483 patients treated with comparator agents (4593 exposures), and the paediatric population base for which safety data are available has doubled to over 1000 patients. The data presented reinforce the favourable safety profile of meropenem. In general, the incidence and pattern of adverse events occurring with meropenem were similar to those of the first carbapenem, imipenem/cilastatin, and to those of the cephalosporin- and clindamycin-based regimens to which it had been compared. The most common adverse events reported for meropenem were diarrhoea (2.5%), rash (1.4%) and nausea/vomiting (1.2%). No adverse event occurred in more than 3% of patient exposures to meropenem, indicating a low overall frequency of adverse events as well as excellent gastrointestinal tolerability. Furthermore, no unexpected adverse events were identified, and the very low incidence of seizures in patients with meningitis was not considered to be drug related. In infections other than meningitis, the incidence of seizures considered by investigators to be related to meropenem treatment was 0.07%. In the new studies that updated the earlier safety data, no new cases of drug-related seizure were reported for any treatment or patient group (meningitis/non-meningitis infections). In conclusion, meropenem is well tolerated and has good CNS and gastrointestinal tolerability when used for the treatment of serious bacterial infections in a wide range of adult and paediatric patient populations.
authors: University of Pittsburgh Medical Center, Pittsburgh, PA 15261, USA. lindenpk@ccm.upmc.edu
authors: Peter
authors: P
authors: Linden
mesh_terms: D000900:Anti-Bacterial Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001424:Bacterial Infections / Q000188:drug therapy; D002986:Clinical Trials as Topic; D006801:Humans; D000077731:Meropenem; D013845:Thienamycins / Q000009:adverse effects* / Q000627:therapeutic use
chemical_list: D000900:Anti-Bacterial Agents; D013845:Thienamycins; D000077731:Meropenem
references: Pediatr Infect Dis J. 1999 Jul;18(7):581-90
references: 10440432
references: J Child Neurol. 2005 May;20(5):456-7
references: 15968935
references: J Antimicrob Chemother. 2003 Jun;51(6):1339-50
references: 12746372
references: Scand J Infect Dis. 1999;31(1):3-10
references: 10381210
references: Clin Microbiol Infect. 2000 Jun;6(6):294-302
references: 11168137
references: Scand J Infect Dis Suppl. 1987;52:65-78
references: 3331044
references: J Antimicrob Chemother. 1998 Oct;42(4):563-4
references: 9818768
references: J Antimicrob Chemother. 1986 Dec;18 Suppl E:193-202
references: 3469194
references: Diagn Microbiol Infect Dis. 2005 Dec;53(4):247-56
references: 16360548
references: Drugs. 2003;63(17):1855-78
references: 12921489
references: Am J Med. 1988 May;84(5):911-8
references: 3284342
references: J Antimicrob Chemother. 2001 Jan;47(1):43-50
references: 11152430
references: Diagn Microbiol Infect Dis. 2005 Dec;53(4):257-64
references: 16360549
references: Drugs. 1996 Jan;51(1):99-136
references: 8741235
references: Int J Antimicrob Agents. 1998 May;10(2):107-17
references: 9716287
references: Surg Infect (Larchmt). 2005 Fall;6(3):269-82
references: 16201937
references: Pharmacotherapy. 2007 Jan;27(1):137-42
references: 17192167
references: Antimicrob Agents Chemother. 2006 Oct;50(10):3473-5
references: 17005836
references: Antimicrob Agents Chemother. 2002 Nov;46(11):3506-11
references: 12384357
references: Clin Ther. 2006 Aug;28(8):1164-74
references: 16982293
references: Curr Med Res Opin. 2005 May;21(5):785-94
references: 15969878
references: Rev Infect Dis. 1985 Jul-Aug;7 Suppl 3:S528-36
references: 3901217
references: Clin Infect Dis. 2005 Jun 1;40(11):1586-90
references: 15889354
references: Ann Pharmacother. 2005 Mar;39(3):533-7
references: 15701769
references: Diagn Microbiol Infect Dis. 2007 Feb;57(2):207-15
references: 16949243
references: Drugs. 2000 Mar;59(3):653-80
references: 10776838
references: J Microbiol Immunol Infect. 2001 Dec;34(4):275-80
references: 11825008
references: Pediatr Infect Dis J. 2001 Jan;20(1):19-24
references: 11176562
references: Diagn Microbiol Infect Dis. 2005 Dec;53(4):265-71
references: 16360550
references: Xenobiotica. 1993 Nov;23(11):1311-23
references: 8310714
references: Int J Antimicrob Agents. 1999 Feb;11(2):107-13
references: 10221413
references: Intensive Care Med. 2005 Sep;31(9):1293-4
references: 16170544
references: Rev Esp Quimioter. 2005 Mar;18(1):39-44
references: 15915231
references: Chin Med J (Engl). 2002 Dec;115(12):1849-54
references: 12622937
references: J Antimicrob Chemother. 1995 Jul;36 Suppl A:207-23
references: 8543496
references: CMAJ. 2004 Jul 6;171(1):51-8
references: 15238498
references: J Antimicrob Chemother. 1997 Feb;39(2):295-6
references: 9069562
references: Drugs. 2000 Sep;60(3):619-46
references: 11030471
references: Int J Antimicrob Agents. 2006 Jan;27(1):69-72
references: 16343857
references: Arch Intern Med. 1989 Aug;149(8):1881-3
references: 2669668
references: J Clin Pharm Ther. 2006 Aug;31(4):393-6
references: 16882111
references: J Allergy Clin Immunol. 1988 Aug;82(2):213-7
references: 2457043
references: J Antimicrob Chemother. 2006 Feb;57(2):176-89
references: 16344285
references: Ther Drug Monit. 1998 Aug;20(4):396-400
references: 9712464
references: Pediatr Infect Dis J. 1991 Feb;10(2):122-5
references: 2062603